GRACELL BIOTECHNOLOGIES INC's ticker is GRCL and the CUSIP is 38406L103. A total of 37 filers reported holding GRACELL BIOTECHNOLOGIES INC in Q1 2021. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $2,415,355 | -19.1% | 1,298,578 | 0.0% | 0.01% | -25.0% |
| Q4 2022 | $2,986,729 | -28.6% | 1,298,578 | 0.0% | 0.01% | -33.3% |
| Q3 2022 | $4,181,000 | -41.5% | 1,298,578 | 0.0% | 0.01% | -36.8% |
| Q2 2022 | $7,142,000 | +136.0% | 1,298,578 | 0.0% | 0.02% | +171.4% |
| Q1 2022 | $3,026,000 | -61.4% | 1,298,578 | 0.0% | 0.01% | -53.3% |
| Q4 2021 | $7,843,000 | -56.8% | 1,298,578 | -0.8% | 0.02% | -57.1% |
| Q3 2021 | $18,150,000 | +17.7% | 1,308,578 | +10.3% | 0.04% | +20.7% |
| Q2 2021 | $15,416,000 | -15.9% | 1,185,889 | -0.4% | 0.03% | -19.4% |
| Q1 2021 | $18,340,000 | – | 1,190,915 | – | 0.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Vivo Capital, LLC | 10,881,144 | $31,337,695 | 3.43% |
| Sio Capital Management, LLC | 2,081,216 | $5,993,902 | 1.86% |
| Pivotal bioVenture Partners Investment Advisor LLC | 1,375,000 | $3,960,000 | 1.58% |
| TCG Crossover Management, LLC | 3,038,889 | $8,752,000 | 1.29% |
| Logos Global Management LP | 2,525,000 | $7,272,000 | 0.97% |
| SPHERA FUNDS MANAGEMENT LTD. | 1,531,497 | $4,410,711 | 0.80% |
| Orbimed Advisors | 9,308,726 | $26,809,131 | 0.57% |
| GREAT POINT PARTNERS LLC | 579,667 | $1,669,441 | 0.30% |
| Temasek Holdings (Private) Ltd | 9,901,940 | $28,517,587 | 0.17% |
| TANG CAPITAL MANAGEMENT LLC | 159,087 | $458,171 | 0.06% |